LIPTRUZET 10 mg/40 mg, comprimé pelliculé — plaquette(s) aluminium de 90 comprimé(s)
Medicine package · Base de données publique des médicaments (BDPM), ANSM, HAS et Assurance Maladie · France
-
CIP13
3400928005618 -
CIP7
2800561 -
CIS
68921356
What the source publishes
- Holder
- ORGANON FRANCE
- Active ingredients
- ATORVASTATINE, ÉZÉTIMIBE, ATORVASTATINE CALCIQUE TRIHYDRATÉE
- Form
- comprimé pelliculé
- Package
- plaquette(s) aluminium de 90 comprimé(s)
- Routes
- orale
- Administrative status
- authorised
- Supply regime
- liste I
- Marketing status
- Déclaration de commercialisation
- Authorised on
- 2014-09-12
- Prescription
- Prescription or restricted
Names this record is found by
- LIPTRUZET 10 mg/40 mg, comprimé pelliculé — plaquette(s) aluminium de 90 comprimé(s)
- LIPTRUZET 10 mg/40 mg, comprimé pelliculé
- ATORVASTATINE
- ÉZÉTIMIBE
- ATORVASTATINE CALCIQUE TRIHYDRATÉE
Complete source data
{
"cis": "68921356",
"cip7": "2800561",
"form": "comprimé pelliculé",
"name": "LIPTRUZET 10 mg/40 mg, comprimé pelliculé — plaquette(s) aluminium de 90 comprimé(s)",
"cip13": "3400928005618",
"holder": "ORGANON FRANCE",
"routes": [
"orale"
],
"holders": [
"ORGANON FRANCE"
],
"currency": "EUR",
"marketed": true,
"bdmStatus": null,
"useDomain": "unknown",
"publicPrice": "61.02",
"authorisedOn": "2014-09-12",
"compositions": [
{
"name": "ATORVASTATINE",
"nature": "FT",
"strength": "40 mg",
"linkageNumber": "2",
"substanceCode": "19809",
"dosageReference": "un comprimé",
"pharmaceuticalElement": "comprimé"
},
{
"name": "ÉZÉTIMIBE",
"nature": "SA",
"strength": "10 mg",
"linkageNumber": "1",
"substanceCode": "73242",
"dosageReference": "un comprimé",
"pharmaceuticalElement": "comprimé"
},
{
"name": "ATORVASTATINE CALCIQUE TRIHYDRATÉE",
"nature": "SA",
"strength": null,
"linkageNumber": "2",
"substanceCode": "92464",
"dosageReference": null,
"pharmaceuticalElement": "comprimé"
}
],
"sourceStatus": "Présentation active",
"supplyRegime": "liste I",
"dispensingFee": "2.76",
"medicinePrice": "58.26",
"regionalRules": "not-collected",
"targetSpecies": [],
"specialityName": "LIPTRUZET 10 mg/40 mg, comprimé pelliculé",
"marketingStatus": "Déclaration de commercialisation",
"publicationDates": {
"CIS_bdpm": "2026-01-08",
"CIS_CIP_bdpm": "2026-11-19",
"CIS_CPD_bdpm": "2026-01-08",
"CIS_COMPO_bdpm": "2026-01-08"
},
"specialityListed": true,
"useDomainEvidence": {
"basis": "unreviewed",
"field": null,
"value": null,
"version": 1,
"sourceId": "fr.ansm.bdpm"
},
"collectiveApproval": "oui",
"packageDescription": "plaquette(s) aluminium de 90 comprimé(s)",
"patientEligibility": "not-assessed",
"reimbursementRates": [
"65%"
],
"marketingDeclaredOn": "2019-09-30",
"targetSpeciesStatus": "not-reported",
"additionalMonitoring": false,
"administrativeStatus": "authorised",
"prescriptionCategory": "prescription-or-restricted",
"activeIngredientNames": [
"ATORVASTATINE",
"ÉZÉTIMIBE",
"ATORVASTATINE CALCIQUE TRIHYDRATÉE"
],
"authorisationProcedure": "Procédure décentralisée",
"prescriptionConditions": [
"liste I"
],
"reimbursementIndications": "Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- chez les adultes avec hypercholestérolémie (certains types uniquement) ou dyslipidémie mixte si elle ne peut être contrôlée par une statine utilisée seule <br>- chez les patients recevant déjà un traitement avec les mêmes principes actifs que ceux contenus dans ce médicament, dans le cadre d'un traitement de substitution. ; JOURNAL OFFICIEL ; 03/11/15",
"authorisationSourceStatus": "Autorisation active",
"europeanAuthorisationNumber": null,
"presentationAdministrativeStatus": "authorised"
}
Read this record from your own software
The same record, with every field and its provenance, is one request away. An API key is free and works immediately.
curl -G "https://api.medifontis.com/v1/drugs/record" \
-H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
--data-urlencode "country=fr" \
--data-urlencode "sourceId=fr.ansm.bdpm" \
--data-urlencode "id=fr:ansm:packages:3400928005618"